Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban] and Determine Cost of Therapy with invasive or Conservative strategy) - TIMI 18 trial.
Concern over escalating health care costs has led to increasing focus on economics and assessment of outcome measures for expensive forms of therapy.
This is being investigated in the Treat Angina With Aggrastat [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS) - TIMI 18 trial, a randomized trial comparing outcome of patients with unstable angina or non-Q-wave myocardial infarction treated with tirofiban and then randomized to an invasive versus a conservative strategy.
Hospital and professional costs initially and over 6 months, including outpatient costs, will be assessed.
Hospital costs will be determined for patients in the United States from the UB92 formulation of the hospital bill, with costs derived from charges using departmental cost to charge ratios.
Professional costs will be determined by accounting for professional services and then converted to resource units using the Resource Based Relative Value Scale and then to costs using the Medicare conversion factor.
Follow-up resource consumption, including medications, testing and office visits, will be carefully measured with a Patient Economic Form, and converted to costs from the Medicare fee schedule.
Health-related quality of life will be assessed with a specific instrument, the Seattle Angina Questionnaire, and a general instrument, the Health Utilities Index at baseline, 1, and 6 months.
The Health Utilities Index will also be used to construct a utility. (...)
Mots-clés Pascal : Angine poitrine, Tirofiban, Analyse coût efficacité, Economie santé, Qualité vie, Chimiothérapie, Traitement, Pronostic, Homme, Inhibiteur thromboagrégation, Appareil circulatoire pathologie, Cardiopathie coronaire
Mots-clés Pascal anglais : Angina pectoris, Tirofiban, Cost efficiency analysis, Health economy, Quality of life, Chemotherapy, Treatment, Prognosis, Human, Antiplatelet agent, Cardiovascular disease, Coronary heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0124682
Code Inist : 002B02G. Création : 16/11/1999.